Please login to the form below

Not currently logged in
Email:
Password:

GSK announces WHO intestinal worm plan

GlaxoSmithKline has announced a five-year plan with the World Health Organization to provide extra albendazole to treat intestinal worms

GlaxoSmithKline (GSK) has announced a five-year plan working with the World Health Organization (WHO) to expand its donation of albendazole for children at risk of intestinal worms, also known as soil-transmitted helminths (STH).

GSK has said it will increase production capacity of the drug following new investments in factories in South Africa and India. It is estimated an extra 400 million treatments will be provided per year, with shipments expected to commence in late 2011.

"Albendazole is a safe, effective and easy to administer treatment for children infected with soil-transmitted helminths, bringing rapid results with long-term benefits," said Dr Margaret Chan, director-general of the WHO.

She continued: "The GSK donation means that many millions more will benefit as part of a strategy that can break the cycle of poverty, ill health, poor school performance and lost productivity."

The commitment comes at the launch of the WHO's first report on neglected tropical diseases - a set of tropical diseases, including STH, which persist only amongst the poorest populations.

"We commend the WHO's leadership to increase the visibility of these disease to the global health community," said Andrew Witty, CEO of GSK. "Today marks another significant commitment by GSK and I hope will help to make a major difference to the lives of people in those countries facing these diseases"

According to the WHO, neglected tropical diseases affect one billion people worldwide, contributing to the weakening of already impoverished countries.

The WHO report aims to convince governments and organisations of the significance of these diseases to encourage greater efforts and investment in their control.

14th October 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics